Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy

Cancer Immunol Immunother. 2020 Sep;69(9):1937-1941. doi: 10.1007/s00262-020-02644-2. Epub 2020 Jun 25.

Authors

Melissa J Danesh^#¹, Patrick M Mulvaney^#², Naoka Murakami³, Leonardo V Riella³, Ann W Silk⁴, Glenn J Hanna⁴, Chrysalyne D Schmults²

Affiliations

¹ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. [email protected].
² Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
³ Division of Nephrology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁴ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

^# Contributed equally.

No abstract available

Publication types

Letter

MeSH terms

Adrenal Cortex Hormones / therapeutic use*
Aged
Allografts
Antibodies, Monoclonal, Humanized / therapeutic use*
Female
Graft Rejection / drug therapy
Graft Rejection / immunology
Graft Rejection / prevention & control*
Humans
Immunotherapy / methods
Kidney Transplantation / adverse effects*
Male
Methylprednisolone / therapeutic use
Middle Aged
Prednisone / therapeutic use
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Programmed Cell Death 1 Receptor / immunology

Substances

Adrenal Cortex Hormones
Antibodies, Monoclonal, Humanized
PDCD1 protein, human
Programmed Cell Death 1 Receptor
cemiplimab
pembrolizumab
Prednisone
Methylprednisolone

Grants and funding

K08 DK120868/DK/NIDDK NIH HHS/United States